STOCK TITAN

Cogent Biosciences, Inc. - $COGT STOCK NEWS

Welcome to our dedicated page for Cogent Biosciences news (Ticker: $COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cogent Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cogent Biosciences's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
Cogent Biosciences, Inc.

Nasdaq:COGT

COGT Rankings

COGT Stock Data

697.02M
80.04M
0.14%
100.15%
11.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About COGT

unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act